IDEXX Laboratories, Inc. vs Under Armour Inc Class A — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while Under Armour Inc Class A trades at $4.92 (market cap $2.07B). The key difference: IDEXX Laboratories, Inc. is far larger — about 19.5× Under Armour Inc Class A's market cap, and Under Armour Inc Class A is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Under Armour Inc Class A for 99 Days on average.
| IDXX | UAA | |
|---|---|---|
Market Cap | $40.43B | $2.07B |
Volume | 692,164 | 12,050,442 |
Sector | Health | Consumer Cyclical |
52-Week High | $766.68 | $8.14 |
52-Week Low | $504.70 | $4.17 |
Typical Hold Time | 46 Days | 99 Days |
Enterprise Value | $41.32B | $3.05B |
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $519.87, up 2.61% on the day, with a bearish technical signal from moving averages but strong fundamentals including a 25.03% net income margin and consistent earnings beats. Revenue grew to $4.3B in 2025, and the company recently acquired CoVetAI to enhance veterinary workflow intelligence, signaling strategic expansion.
The stock's outlook is supported by robust profitability and analyst consensus, but faces headwinds from technical weakness and potential market volatility. With a $665 price target implying significant upside, the primary risks include competitive pressures and execution of growth initiatives amid economic uncertainties.
Under Armour (UAA) trades at $4.93, up 2.28% on the day, with a mixed technical outlook showing a bullish moving average signal but a neutral oscillator stance. The company reported a net loss of $201.27M in 2025, with revenue declining to $5.16B, though recent quarterly earnings have beaten expectations. Analyst consensus is a 'Hold' with a $5.79 price target, while news highlights the company's focus on product simplification and margin improvement amid softer demand.
The outlook remains challenging due to persistent revenue weakness and negative profitability, but cost discipline and international growth offer potential stabilization. Key risks include execution of the turnaround plan and competitive pressures. The stock presents a speculative opportunity for investors betting on a successful brand transformation, but requires careful risk assessment given the current financial headwinds.
Trailing returns across standard periods
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America and other territories. Consumers of its apparel include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. Under Armour also operates a digital fitness app called MapMyFitness. The Baltimore-based company was founded in 1996.
Read more on UAA →